BioMelbourne Network
Progressing BioIndustry
News and Opinions
2011
December
Allied Healthcare Group appoint Dr Julian Chick as COO
BRISBANE, Australia, 7 December 2011. Allied Healthcare Group (ASX:AHZ) today announced that Dr Julian Chick has been appointed to the position of Chief Operating Officer. Dr Chick will help drive the commercialisation of the Company's product pipeline and develop further commercial opportunities for the Group.
Dr Chick will retain his position as Non-Executive Director of Coridon, the DNA v... read more…
More Support for Australian Innovators
Starting tomorrow Australian entrepreneurs will not have to repay Early Stage Commercialisation grants for businesses developing a new product, process, or service. Plus, these grants will be available to more businesses, as the annual turnover limit for applicants will rise from $20 million to $50 million.
In addition, growing businesses that can benefit from access to skilled managers n... read more…
Patrys Announces Oversubscribed Capital Raising of AU$3.4 Million
Melbourne, Australia; 2 December, 2011: The private placement of approximately 113.5 million new shares at an issue price of AU$0.03 per share will rank equally with existing shares, and will be conducted in two tranches.
A total of 37 million new shares are to be issued under the 15% placement capacity of Patrys, with settlement expected to occur on 7 December 2011. The balance of new shar... read more…
Victorian Government announces biotechnology advisory council
Minister for Technology Gordon Rich-Phillips today announced the appointment of Victoria’s inaugural Biotechnology Advisory Council, which will be chaired by Professor Ian Gust.
The Victorian Biotechnology Advisory Council (VBAC) will provide advice to government on current and emerging opportunities and threats to the sector, as well as contributing to the implementation of the Victorian Coal... read more…
Genetic Technologies Executes Settlement and License Agreement with AutoImmun Diagnostika GmbH
1 December 2011In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to report it has now executed a Settlement and License Agreement with AutoImmun Diagnostika GmbH ("AID") of Strassberg, Germany.Under the terms of the Agreement, AID is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA tech... read more…
November
PBS growing at just 1.6%
30 November 2011. New Govt figures show PBS growing at just 1.6%.
The latest Commonwealth Department of Health and Ageing's annual review of the Pharmaceutical Benefits Scheme shows that the program grew by just 5.2 per cent in 2010-11 or 1.6 per cent in real terms.
This follows yesterday's MYEFO, showing lower PBS growth this financial year.
Medicines Australia chief executive Dr Brendan ... read more…
Blackburn Fellowships celebrate women in research
The outstanding achievements of Australian Nobel Laureate Professor Elizabeth Blackburn have been recognised through a new fellowship from the National Health and Medical Research Council (NHMRC) awarded to top female Research Fellows.
This important new NHMRC Fellowship was announced today by Minister for Health and Ageing Nicola Roxon and Minister for Mental Health and Ageing Mark Butler.“Th... read more…
Victorian-based CRCs acknowledged as nations best
Minister for Innovation, Services and Small Business Louise Asher today congratulated three Victorian-based Cooperative Research Centres (CRCs) on their successful bids for Commonwealth funding.
Automotive Australia 2020 CRC, CRC for Polymers and the CRC for Water Sensitive Cities will receive a total of $70.5 million from the Commonwealth CRC Program.
“All three CRCs prepared a strong bid in... read more…
Immuron signs distribution deal worth up to $113 million
Immuron has secured a multi-market distribution deal worth up to C$115.5 million ($112.7m) for its debut OTC antibody product, Travelan.
Canadian pharmaceutical company Paladin Labs has become the exclusive distributor for Immuron's Travelan travellers' diarrhoea treatment in Canada, Latin America and sub-Saharan Africa.Under the partnership terms, Immuron will be entitled to an upfront licens... read more…
Opinion: Outright Ban on Gene Patents Rejected
Australian Government responds to recent inquiries into gene patentability: outright ban rejected.
By Dr Tania Obranovich, Partner
Davies Collison Cave
The Federal Government yesterday tabled its response to three recent inquiries into reform of Australia's patent system—including the Senate Community Affairs Committee inquiry into gene patents, the Advisory Council on Intellectual Prop... read more…
